Skip to main content

Table 2 Current active trials in HNSCC testing the safety and efficacy of novel drug combinations

From: Genomically personalized therapy in head and neck cancer

Trials

Trial phase

Drug 1

Drug 2

Pathway 1

Pathway 2

Setting

Status

NCT01716416

1

Pazopanib

Cetuximab

Angiogenesis

EGFR

Recurrent, metastatic

Recruiting

NCT02499120

2

Palbociclib

Cetuximab

Cell cycle

EGFR

Plcebo controlled randomized phase II, recurrent, metastatic

Recruiting

NCT02101034

1,2

Palbociclib

Cetuximab

Cell cycle

EGFR

Recurrent, metastatic

Recruiting

NCT01711541

1, 2

Veliparib

Chemotherapy

DNA repair

EGFR

Recurrent, metastatic

Recruiting

NCT02538627

1

MM-151

MM-121

EGFR

ERBB

Recurrent, metastatic

Recruiting

NCT02501096

1, 2

Pembrolizumab

Lenvatinib

Immune

Angiogenesis

Recurrent, metastatic

Recruiting

NCT02454179

2

Pembrolizumab

ACP-196

Immune

Bruton Tyrosine Kinase

Recurrent, metastatic

Recruiting

NCT02646748

1

Pembrolizumab

INCB039110/INCB050465

Immune

JAK/PI3K

Recurrent, metastatic

Recruiting

NCT01468896

1, 2

Recombinant interleukin-2

Cetuximab

Immune

EGFR

Recurrent, metastatic

Active, not recruiting

NCT02507154

1, 2

NK cells

Cetuximab

Immune

EGFR

Recurrent, metastatic

Recruiting

NCT02643550

1, 2

Monalizumab

Cetuximab

Immune

EGFR

Recurrent, metastatic

Recruiting

NCT02110082

1

Urelumab

Cetuximab

Immune

EGFR

Recurrent, metastatic

Active, not recruiting

NCT02124850

1

Motolimod/Nivolumab

Cetuximab

Immune

EGFR

Stage II-IVA, neoadjuvant

Recruiting

NCT02586987

1

MEDI4736

Selumetinib

Immune

MEK

Recurrent, metastatic

Recruiting

NCT01871311

1

Nilotinib

Cetuximab

Kit

EGFR

Recurrent, metastatic

Recruiting

NCT02277197

1

Ficlatuzumab

Cetuximab

MET

EGFR

Recurrent, metastatic

Recruiting

NCT01332266

1, 2

E7050

Cetuximab

MET

EGFR

Recurrent, metastatic

Recruiting

NCT02205398

1

INC280

Cetuximab

MET

EGFR

Recurrent, metastatic

Recruiting

NCT01285037

1

LY2801653

Cetuximab

MET

EGFR

Recurrent, metastatic

Recruiting

NCT01602315

1b, 2

BYL719

Cetuximab

PI3K

EGFR

Recurrent, metastatic

Active, not recruiting

NCT01488318

2

Dasatinib

Cetuximab

Scr

EGFR

Recurrent, metastatic

Recruiting